Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26523246
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26523246
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Curr+Oral+Health+Rep
2015 ; 2
(4
): 202-211
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Oral Mucositis Induced By Anticancer Therapies
#MMPMID26523246
Al-Ansari S
; Zecha JA
; Barasch A
; de Lange J
; Rozema FR
; Raber-Durlacher JE
Curr Oral Health Rep
2015[]; 2
(4
): 202-211
PMID26523246
show ga
Oral mucositis induced by conventional cytotoxic cancer therapies is a common and
significant clinical problem in oncology. Mucositis symptoms, which include
severe pain, may lead to dose reductions and unplanned interruptions of
chemotherapy and/or radiotherapy, and often affect patients' quality of life. In
addition, ulcerative mucositis represents a risk factor for local or systemic
infectious complications that may be life-threatening in immunosuppressed
patients. The development of biologically based targeted cancer therapies, which
aim to block the growth, spread, and survival of tumors by interfering with
specific molecular targets, may have reduced mucosal injury, but did not
eliminate it. This article will review the epidemiology, pathobiology, and
management of oral mucositis associated with conventional cytotoxic therapies for
malignant diseases and will briefly summarize emerging information on oral
mucosal injury associated with targeted therapies. Considerations for future
research aimed at the development of more efficient and effective supportive care
approaches will be presented, with emphasis on the contribution of dental
researchers and clinicians in these efforts.